Background: We aimed to clarify renal functional changes long term and serious urological complications in women with cervical cancer who undergo radical hysterectomy followed by pelvic radiotherapy and/or platinum-based chemotherapy to treat the initial disease. Methods: Data on 380 women who underwent radical hysterectomy at the National Kyushu Cancer Center from January 1997 to December 2013 were reviewed. Main outcome measures were the estimated glomerular filtration rate (eGFR) and monitored abnormal urological findings. Results: Postoperative eGFR was significantly lower than preoperative eGFR in 179 women with surgery alone and in 201 women with additional pelvic radiotherapy and/or chemotherapy (both P < 0.01). Two types of univariate analyses for eGFR reduction in women after treatment showed that older age, advanced stage, pelvic radiotherapy, and platinum-based chemotherapy were significant variables on both analyses. Two types of multivariate analyses showed that platinum-based chemotherapy or pelvic radiotherapy were associated with impaired renal function (odds ratio 1.96, 95% confidence interval 1.08-3.54 and odds ratio 2.85, 95% confidence interval 1.12-7.24, for the respective analyses). There was a higher rate of bladder wall thickening in women with pelvic radiotherapy had than those without it (17.4% vs. 2.7%, P < 0.01). One serious urological complication (intraperitoneal rupture of the bladder) occurred among women who underwent pelvic radiotherapy (0.6% vs. 0%). Conclusions: Surgeons should be aware that eGFR is reduced after platinum-based chemotherapy and/or postoperative pelvic radiotherapy. Serious and life-threatening urological complications are rare, but surgeons should be aware of the possibility during the long follow-up.
Introduction
Recently, radiotherapy with chemotherapy has been adopted for adjuvant treatment of women with high-risk factors after major surgery for cervical cancer. Radical hysterectomy, radiotherapy and chemotherapy may have adverse effects on renal and urological functions. Indeed, previous prospective studies reported major genitourinary complications associated with using postoperative radiotherapy for cervical cancer as concurrent chemoradiation therapy (CCRT) with a median follow-up of 34-44 months (1) (2) (3) (4) (5) (6) . Few reports, however, have clarified long-term renal functional changes in women who undergo radical hysterectomy with/without postoperative radiotherapy with/without chemotherapy. In addition, few reports have described severe urological complications from radiotherapy after radical hysterectomy (7), even though there have been studies on primary radiotherapy for cervical cancer (8, 9) . In the era of CCRT, investigating long-term renal function and urological complications after postoperative CCRT appears to be important.
We conducted a retrospective observational study in which we investigated changes in renal function using the estimated glomerular filtration rate (eGFR) and long-term serious urological adverse events in women with cervical cancer after radical hysterectomy with/without postoperative pelvic radiotherapy and/or platinumbased chemotherapy based on long-term observations.
Patients and methods
All procedures in the current study were in accordance with the ethical standards of the Institutional Research Committee, the ethical guidelines of the Ministry of Health, Labour, and Welfare of Japan, and the 1964 Helsinki Declaration and its later amendments. In the present study, we analyzed only the data and medical or radiological images for which the women gave permission to use at their first consultation at our hospital. No patient-identifiable data are reported, and no direct interaction with patients was necessary.
We reviewed admission and discharge records, as well as surgical databases, to identify women who had undergone radical hysterectomy performed by the Gynecology Service of the National Kyushu Cancer Center from January 1997 to December 2013. For the women who underwent radical hysterectomy, we reviewed their treatment summaries, medical records of their latest consultations, the latest computed tomography (CT) images and/or CT reports, and outpatient summaries if available. Patient background characteristics such as age, cancer type, clinical stage, adjuvant radiotherapy to the pelvis, neoadjuvant chemotherapy (NAC) or adjuvant chemotherapy and serum creatinine (sCr) levels were obtained from article-and digital-based records from the National Kyushu Cancer Center. We also obtained the data on intraoperative blood loss, postoperative urine volume and postoperative dehydration judging from postoperative tachycardia, thirst and the blood urea nitrogen/sCr ratio of ≥20.
Indications for postoperative radiation therapy in our institution were as follows: Stage IIB and pT2B cervical cancer, full-thickness cancer invasion of the cervix and pelvic lymph node metastasis. Intravaginal brachytherapy was used when the cancer invasion was <1 cm from the vaginal margin. Pelvic external radiotherapy for recurrent pelvic diseases was performed in two women who were excluded from the whole-pelvis external radiotherapy group. These women underwent adjuvant chemotherapy for initial diseases before pelvic radiotherapy for recurrent diseases and were included in the adjuvant chemotherapy group. Another woman, who underwent para-aortic external radiotherapy without pelvic external radiotherapy for her initial disease, was included in the cisplatin CCRT group (Table 1) .
Pretreatment levels of sCr were used before surgery because most women were healthy enough to undergo surgery. Posttreatment levels of sCr were used if serum chemistry was checked when the patient was healthy, without recurrence or severe intercurrent disease. At the National Kyushu Cancer Center, the normal sCr level for women is ≤0.7 mg/dl. We calculated the eGFR using the formula of the Japanese Society of Nephrology for Japanese women (10) 
The eGFR was calculated to compare renal function before treatment with that at the last consultation. sCr levels and ages before surgery and at the last consultation were used for the calculation. Chronic kidney disease was categorized into five groups: Stage I, eGFR ≥90 ml/min/ cases in the present study.) Chemotherapy in the present study included platinum-based regimens. Cisplatin was used in CCRT at a dose of 30 or 40 mg/m 2 per week for up to 6 weeks. Other cisplatin-based or carboplatinbased regimens were used for NAC and adjuvant chemotherapy. We excluded patients who received NAC from statistical analyses because we needed to investigate renal function and urological complications after radical hysterectomy. Indications for adjuvant chemotherapy were nonsquamous cell carcinoma-type cancer and para-aortic lymph node metastasis. )-because a colon cancer was also resected when radical hysterectomy for the cervical cancer was performed. This case was included in the analysis on urological complications but was partially excluded from the analysis on renal function because the mFOLFOX6 regimen was not a usual treatment for women with cervical cancer.
Bladder wall thickening, hydronephrosis and renal atrophy were observed on CT images and/or in CT reports. These conditions were diagnosed by attending radiologists. Hydronephrosis caused by a primary or recurrent tumor was excluded. Early surgical complications (e.g. vesicovaginal fistula, ureteral obstruction) were also One woman underwent para-aortic ERT without pelvic ERT, and had the cisplatin regimen at CCRT. Another women underwent a chemotherapy for a colon cancer lesion which resected at the same time of radical hysterectomy. excluded. Neurogenic bladder signs (e.g. urinary incontinence, the need for clean intermittent catheterization), and neurogenic bladder symptoms (e.g. dysuria, urination mostly relying on abdominal pressure) were identified through medical records.
Statistics
Background characteristics, eGFR levels, and urological complications were determined using descriptive statistics or contingency tables. Comparisons of eGFRs under various conditions were tested using Student's t-test or paired t-test and the Mann-Whitney U test or Wilcoxon's signed-rank test, as appropriate. Comparisons between dichotomized factors were made using Fisher's exact test. Risk factors for impaired postoperative renal function were assessed using Fisher's exact test and multiple logistic regression analysis. All P values were two-sided. P < 0.05 was considered to indicate statistical significance. Pretreatment and posttreatment eGFRs over time were analyzed using the Friedman test and Bonferroni adjustment.
All statistical analyses were performed using EZR, version 1.32 (Saitama Medical Center, Jichi Medical University, Saitama, Japan) (12), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). This software is a modified version of R commander that is designed to add statistical functions frequently used in biostatistics.
Results

Patient prognosis during the follow-up period
A total of 403 women underwent radical hysterectomy from January 1997 to December 2013 at the National Kyushu Cancer Center. The median follow-up period was 85 months [range 1-221 months, interquartile range (IQR) 41-119]. In all, 51 women died of cervical cancer during the study period, including 44 of 194 (22.7%) who required pelvic radiotherapy and 7 of 209 (3.3%) who did not. The women who needed pelvic radiotherapy had a higher mortality rate than those who did not (P < 0.01).
Patient background characteristics
Patients' background characteristics are shown in Table 1 . Among the 403 women who received NAC, 23 were excluded. The remaining 380 underwent radical hysterectomy. In all, 161 of the 380 (42.4%) women with cervical cancer underwent postoperative pelvic external radiotherapy (Table 1) , and 29 of the 161 women underwent intravaginal brachytherapy as well. Ten women underwent only intravaginal brachytherapy (Table 1) .
We treated patients with various doses of pelvic external and intravaginal radiotherapy (Table 1) . Since 2012, a group of 22 patients were treated with an external dose of 50.4 Gy/28 Fr, and 9 of the 22 women also underwent intensity-modulated radiation therapy (Table 1) .
A total of 166 women were given chemotherapy for initial diseases, including 17 who received chemotherapy for recurrent diseases as well. sCr levels measured before surgery and before chemotherapy for recurrent diseases were used to analyze these 17 women (Table 1) . Four women who received chemotherapy alone for recurrent diseases and had undergone postoperative radiotherapy alone for the initial diseases were included in the pelvic external radiotherapy group (Table 1) . The mean observation period on sCr levels was 80.3 months (95% CI 75.6-85.0) or a median of 83 months (range 0-221 months, IQR 40-119).
eGFR before and after treatment Pretreatment and posttreatment eGFRs were compared in the same women (whole population, radical abdominal hysterectomy (RAH) alone, and RAH + radiotherapy and/or chemotherapy) ( Table 2) . Posttreatment eGFR was significantly lower than pretreatment eGFR for each group (P < 0.01, respectively) ( Table 2 ). Pretreatment sCr levels of the whole population were 0.34-1.03 mg/dl (median 0.56, IQR 0.51-0.61), and posttreatment sCr levels of the whole population were 0.33-1.59 mg/dl (median 0.6, IQR 0.54-0.69). Pretreatment sCr levels in women who underwent radical hysterectomy alone were 0.34-0.93 mg/dl (median 0.56, IQR 0.51-0.60), and posttreatment levels were 0.39-1.00 mg/dl (median 0.58, IQR 0.53-0.64).
eGFR main variables were calculated in the pretreatment and posttreatment states ( Table 2 ). Pretreatment eGFR was not significantly lower in women with advanced-stage disease than in those with early-stage disease (P = 0.72) ( Table 2 ).
In the chemotherapy group, after treatment, the mean eGFR in 131 women treated with cisplatin CCRT was 76. women who were treated with carboplatin-based chemotherapy. Among the women with pelvic radiotherapy, 10 women who underwent intravaginal brachytherapy alone were excluded from pelvic external radiotherapy in this analysis (Table 2) .
We used the paired-t test and Student's t-test to analyze the data presented in Table 2 because the sample sizes were large. Data analyzed using the Wilcoxon signed-rank test and Mann-Whitney U test exhibited similar results-i.e. pretreatment eGFR was not significantly lower in women with advanced-stage disease than in those with early-stage disease (P = 0.30). Other factors shown in Table 2 were statistically significant (all, P < 0.01).
Change in eGFR over time
The pretreatment, postoperative state, post-chemotherapeutic state and last consultation eGFR values are shown in Fig. 1 . One woman who underwent the mFOLFOX6 regimen was excluded from this analysis. The eGFR after chemotherapy was significantly reduced compared with that on postoperative day (POD) 7, as analyzed by the Friedman test and Bonferroni adjustment. The eGFR at the last consultation was also significantly reduced compared with that on POD 7. The difference between the pretreatment level of eGFR and the POD 1 level was not statistically significant, and the difference between PODs 1 and 7 levels was also not statistically significant.
Change in eGFR before and after treatment
Pretreatment and posttreatment eGFR grades are shown in Table 3 . Four (1.1%) women with G3 renal function before treatment did not improve to G2 or G1 after treatment. Among the others, 46 (12.1%) of the women had G3 and one (0.3%) had G4 renal function after treatment (Table 3) .
Among 131 women who underwent a weekly cisplatin CCRT regimen, 20 with a total dose of 30-90 mg/m 2 cisplatin were excluded because the dose appeared to be small and the group represented only 15.3% of the women ( Table 1 ). The remaining 111 women were included in the analysis. Six underwent both a cisplatin CCRT regimen and an adjuvant carboplatin-based regimen (Table 3) . A relatively high percentage of women with pelvic radiotherapy and/or chemotherapy were classified as G3 and G4 after treatment compared with those with radical hysterectomy alone (Table 3) . Similarly, a relatively high percentage of women with pelvic radiotherapy and/or chemotherapy had a ≥20% reduction in their eGFR compared with those with radical hysterectomy alone (Table 3) .
Univariate analysis of impaired renal function after treatment
Univariate analysis of suspected variables related to eGFR (Table 2) was performed for impaired renal function in women whose renal dysfunction grade worsened to G3 or G4 after treatment (Table 4) . This reflects the possible correlation of G3 or G4 eGFR with chronic kidney disease, even without albuminuria. Other variables that seem to have some relation to renal function (i.e. diabetes mellitus, hypertension, intraoperative blood loss, postoperative dehydration) were included in this analysis. Intravaginal radiotherapy was also included.
Among the RAH-only group, diabetes mellitus was found in 1.7% (3/179), hypertension in 6.7% (12/179), and dehydration in 24.0% (43/179). Among those who underwent RAH in the adjuvant treatment group, diabetes mellitus was found in 4.0% (8/201), hypertension in 11.9% (24/201), and dehydration in 28.9%
(58/201). The variables were not significantly different on statistical analyses. The mean postoperative urine volume per hour from the end of surgery until the next morning among the RAH-only group was 68.9 cc/h (95% CI 64.8-72.9) and that among those who Chemotherapy without treating recurrence included 131 women with a weekly cisplatin regimen CCRT and 43 with other adjuvant chemotherapy (5 cisplatinbased and 38 carboplatin-based). Six women had both the cisplatin regimen at CCRT and other adjuvant chemotherapy.
CCRT, concurrent chemoradiation therapy; CI, confidence interval; eGFR, estimated glomerular filtration rate; RAH radical hysterectomy, RT radiotherapy. *Significant according to the paired t-test or Student's t-test.
underwent RAH with postoperative radiotherapy and/or chemotherapy was 70.1 cc/h (95% CI, 65.2-74.9). The difference was not significantly different (P = 0.71). The mean intraoperative blood loss among the RAH-only group was 568.5 g (95% CI 505.8-631.1), and among those who underwent RAH with postoperative radiotherapy and/or chemotherapy was 673.9 g (95% CI 620.3-727.6). The difference here was significantly different (P = 0.01). Altogether, 12 women died of their disease within 2 years after the surgery. Among them, two women did not undergo radiotherapy or chemotherapy. The other 10 women did undergo radiotherapy . One woman with G4 underwent pelvic RT and CDDP at CCRT. There were six overlapping cases between the CDDP at CCRT group and Ad CBDCA group. Ad CBDCA, adjuvant carboplatin-based regimen; Ad CDDP, adjuvant cisplatin-based regimen; CDDP at CCRT, cisplatin at concurrent chemoradiation therapy regimen; eGFR, estimated glomerular filtration rate; G, grade, RAH, radical hysterectomy; ERT, external radiotherapy. and/or chemotherapy. The 12 women were excluded from the analysis shown in Table 4 because they had only a short duration of stable urinary function. Women who underwent the mFOLFOX6 regimen for coincidental colon cancer were also excluded from the analysis shown in Table 4 . The patients' age at the time of surgery-not at the time of the final consultation-was used in this analysis because we evaluated the change in eGFR over time. Significant variables were older age, advanced stage, addition of pelvic external radiotherapy and addition of platinum-based chemotherapy (Table 4) . We analyzed the odds ratio for carboplatin (CBDCA) and the addition of CDDP-based chemotherapy on the risk of renal impairment worsening to G3 or G4. The odds ratio for CBDCA was 1.36 (95% CI 0.48-3.38, P = 0.47), and for CDDP-based chemotherapy it was 4.47 (95% CI 2.18-9.48, P < 0.01).
Univariate analysis was also performed in women who had a ≥20% reduction in eGFR (Table 4 ) because the group of women with this reduction comprised less than one-third (27.4%) of the entire population (Table 3) . We considered that a ≥20% reduction in eGFR was uncommon and clinically critical. In this analysis, 12 women who died of disease within 2 years and a woman who underwent mFOLFOX6 were also excluded. Significant variables were advanced stage, addition of pelvic external radiotherapy, and addition of platinum-based chemotherapy (Table 4) .
We analyzed the odds ratio of CBDCA and addition of CDDPbased chemotherapy on ≥20% reduction in eGFR. The odds ratio of CBDCA was 1.35 (95% CI 0.66-2.69, P = 0.39), and for CDDPbased chemotherapy it was 2.32 (95% CI 1.40-3.86, P < 0.01).
Multivariate analysis of impaired renal function after treatment
The nine variables used in the univariate analysis were evaluated using multiple logistic regression ( Table 4 ). The multivariate analysis of renal functional impairment regarding its worsening to G3 or G4 showed that pelvic radiotherapy was the significant variable. Multivariate analysis of women with a ≥20% reduction in eGFR showed that the addition of platinum-based chemotherapy was a significant variable. Other variables were not found to be significant (Table 4) .
We then substituted CDDP-based chemotherapy for platinumbased chemotherapy and performed a similar multivariate analysis. The odds ratio for the CDDP-based chemotherapy on renal impairment worsening to G3 or G4 was 1.94 (95% CI 0.77-4.87, P = 0.16), and the odds ratio of CDDP-based chemotherapy on a ≥20% reduction in eGFR was 1.76 (95% CI 0.89-3.46, P = 0.10).
Comparison between RAH-only and RAH with radiotherapy and/or chemotherapy effects on the posttreatment eGFR using propensity score matching
We created a propensity score to compare the posttreatment eGFR between RAH-only and RAH with radiotherapy and/or chemotherapy. Propensity score matching was applied to the variables, including age, intraoperative blood loss, dehydration, diabetes mellitus, hypertension and pretreatment eGFR.
There were 176 matched pairs. The mean posttreatment eGFR for the RAH-only group was 85.0 ml/min/m 2 (95% CI 82.7-87.2), and that for the RAH with radiotherapy and/or chemotherapy group was 78.0 ml/min/m 2 (95% CI 74.9-81.1). The difference was statistically significant (P < 0.01).
Serious urological complications
Among the 161 (0.6%) women, one experienced spontaneous intraperitoneal rupture of the urinary bladder, which was classified as a late-onset serious urological complication after radical hysterectomy in the radiotherapy group. This patient had Stage IIB cervical adenocarcinoma, for which she had undergone radical hysterectomy and postoperative CCRT using cisplatin. She had also undergone another course of systemic chemotherapy for recurrent disease. The rupture occurred 5 years 10 months after the radical hysterectomy and was relieved by surgery (Table 5 and Fig. 2 ). There were no cases of treatment-induced renal failure.
Other urological complications and pelvic radiotherapy
The associations between urinary complications and pelvic radiotherapy were examined. The mean interval between pretreatment CT and the CT results at the last consultation was 70.1 months (95% CI 65.8-74.3) with a median of 62 months (range 0-221, IQR 38-103). Six women did not undergo posttreatment CT. Adverse events included bladder wall thickening, hydronephrosis, chronic or radiation cystitis, renal atrophy, and neurogenic bladder signs and symptoms (Table 5 ). Two women with renal atrophy had Stage IIB cervical cancer. Signs and symptoms of neurogenic bladder Results are given as the number (%). Among women using CIC, one case of temporary CIC was included in the group with pelvic radiotherapy and in the group without pelvic radiotherapy.
CIC, clean intermittent catheterization; NB, neurogenic bladder. *Significant difference according to Fisher's exact test. were observed in nonradiotherapy and radiotherapy groups (10.5% and 6.2%, respectively, P = 0.20) ( Table 5 ). The rate of bladder wall thickening was significantly higher in women who underwent pelvic radiotherapy than in those who did not (P < 0.01) ( Table 5) .
Discussion
No studies have investigated impaired renal function by examining pretreatment and posttreatment eGFR levels. We used the formula of the Japanese Society of Nephrology for Japanese women (Japanese eGFR formula) to calculate the eGFR (ml/min/1.73 m 2 ) because almost all women in the present study were Japanese (a few were Korean or Chinese). This formula does not include body weight and differs from other eGFR formulas, such as the Cockcroft-Gault formula, which includes body weight. The Cockcroft-Gault formula, however, is not calibrated with the body surface area and the unit is in milliliters per minute. Therefore, it does not reflect the degree of obesity given that the GFR is estimated to be higher among obese people and lower among people with low body weight or who are older. According to the Japanese Society of Nephrology guidelines, 75% of all cases were included in the range of measured values of GFR ± 30% using the Japanese eGFR formula. The Japanese eGFR formula is precisely adjusted for Japanese women, with the exception of those with small amounts of muscle, such as emaciated women or amputees (10, 13) . None of the women in our study had amputated limbs, and all were sufficiently healthy to undergo radical hysterectomy. They did not appear to be emaciated.
CDDP-based chemotherapy was a main part of platinum-based chemotherapy, but it was not an independent, statistically significant factor on the multivariate analyses. We assume that CDDP-based chemotherapy has a close connection with postoperative pelvic external radiotherapy. In most cases, the two modalities were done concurrently. That is, few women underwent RAH and postoperative CDDP-based adjuvant chemotherapy without pelvic external radiotherapy.
One strength of the present study is that it is the first to investigate long-term renal functional changes in women who underwent radical hysterectomy with/without pelvic radiotherapy and/or platinum-based chemotherapy by calculating the eGFR, with a median follow-up of 82 months. A second strength is that we investigated serious urological complications among women treated with postoperative radiotherapy over a long-term observation period.
A previous study reported that radiotherapy induced fibrosis in the genitourinary system (14) . This could cause the urinary bladder wall to harden and might disturb urinary bladder expansion, in turn causing damage to the urinary system. In our study, pelvic radiotherapy and chemotherapy were independent risk factors for renal dysfunction postoperatively. Both pelvic radiotherapy and postoperative chemotherapy have been used after radical hysterectomy when adjuvant therapy is needed. Hence, we need to pay attention to changes in the eGFR, especially when those two modalities are used.
Regarding prophylaxis, a previous study showed that magnesium preloading before cisplatin administration significantly reduced cisplatin-induced nephrotoxicity (15) . We have used mannitol with a cisplatin-containing regimen but have now adopted the use of magnesium preloading. Also, for women who are undergoing a cisplatin-containing regimen, we measure body weight several times a day as well as the urinary volume so as to administer appropriately timed diuretics, if necessary.
Age is a risk factor for renal dysfunction, and the formula for calculating the dose includes the patient's age. In fact, in the present study, age was a risk factor in one of the univariate analyses. The posttreatment eGFR for women who underwent RAH only, however, was higher than that for women who underwent RAH and radiotherapy and/or chemotherapy when age and other factors were matched. In these cases, postoperative pelvic radiotherapy and/or chemotherapy seemed to be independent risk factors. Hypertension and diabetes mellitus are traditional risk factors for chronic kidney disease, but they were not statistically significant variables in this study. Among our study patients, however, a relatively small number of women had these diseases, which might have affected the results.
In the present study, eGFR was significantly reduced at the completion of platinum-based chemotherapy. Also, renal function seemed to start declining at a relatively early stage after postoperative chemotherapy, with renal dysfunction seeming to progress over time.
Only one woman in the present study had a serious urological complication, after radical hysterectomy and pelvic radiotherapy, that required surgical management. This serious complication rate (0.6%) is lower than that stated in a previous study on curative radiotherapy for cervical cancer (8.1%, including spontaneous rupture of the urinary bladder in 2.0%) (9). This previous high incidence rate was reported to be caused by the use of high-dose-rate intrauterine brachytherapy (9) . The present study includes women who underwent intravaginal brachytherapy, but it does not include those who underwent intrauterine brachytherapy. A previous study suggested that hysterectomy-induced neurogenic bladder may cause expansion of a damaged bladder wall secondary to irradiation, causing rupture (7) . In the present study, the rates of signs and symptoms of neurogenic bladder were not different between women with pelvic radiotherapy and those without it. Based on the results of the present study, a thickened bladder wall, possibly induced by fibrosis, could disturb bladder wall expansion, thereby causing a rise in pressure in the urinary bladder.
Limitations of our study are that it was retrospective in nature, and it is a single-center study. Therefore, some bias may have affected the data. A multi-center cohort study is needed to confirm changes in renal function over the long term.
In conclusion, impaired renal function can be identified by assessing the eGFR during long-term follow-up of women with cervical cancer who undergo radical hysterectomy and postoperative pelvic radiotherapy and/or platinum-based chemotherapy for treating their initial disease. Serious urological complications, such as intraperitoneal rupture of the bladder, were rare after postoperative radiotherapy followed by radical hysterectomy. This complication, however, can be life-threatening. Thus, surgeons should be aware of a reduction in eGFR caused by pelvic radiotherapy and/or platinum-based chemotherapy after radical hysterectomy. They should also be mindful of potential radiotherapy-related serious urological complications over the course of a long-term follow-up.
